Cytokinetics Inc Asset Resilience Ratio
Cytokinetics Inc asset resilience ratio. Cytokinetics Inc (CYTK) has an Asset Resilience Ratio of 47.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Cytokinetics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cytokinetics Inc (2002–2025)
Asset resilience ratio of Cytokinetics Inc from 2002 to 2025. This chart shows how Cytokinetics Inc's Asset Resilience Ratio has changed over time. Read Cytokinetics Inc (CYTK) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cytokinetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cytokinetics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $910.41 Million | 47.31% |
| Total Liquid Assets | $910.41 Million | 47.31% |
Asset Resilience Insights
- Very High Liquidity: Cytokinetics Inc maintains exceptional liquid asset reserves at 47.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytokinetics Inc Industry Peers by Asset Resilience Ratio
Compare Cytokinetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Cytokinetics Inc Asset Resilience Ratio by Year (2002–2025)
Cytokinetics Inc asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Cytokinetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.33% | $759.70 Million | $1.42 Billion | -16.67pp |
| 2024-12-31 | 70.00% | $981.16 Million | $1.40 Billion | +9.12pp |
| 2023-12-31 | 60.87% | $501.80 Million | $824.32 Million | -9.78pp |
| 2022-12-31 | 70.66% | $717.00 Million | $1.01 Billion | +27.99pp |
| 2021-12-31 | 42.67% | $358.97 Million | $841.32 Million | -28.72pp |
| 2020-12-31 | 71.39% | $381.07 Million | $533.80 Million | +6.29pp |
| 2019-12-31 | 65.10% | $188.68 Million | $289.81 Million | -8.99pp |
| 2018-12-31 | 74.10% | $156.47 Million | $211.18 Million | +25.36pp |
| 2017-12-31 | 48.74% | $143.69 Million | $294.81 Million | -3.79pp |
| 2016-12-31 | 52.53% | $89.38 Million | $170.14 Million | +12.29pp |
| 2015-12-31 | 40.24% | $46.37 Million | $115.24 Million | -7.15pp |
| 2014-12-31 | 47.39% | $63.01 Million | $132.97 Million | -21.82pp |
| 2013-12-31 | 69.20% | $57.57 Million | $83.19 Million | -6.99pp |
| 2012-12-31 | 76.20% | $59.09 Million | $77.55 Million | +18.99pp |
| 2011-12-31 | 57.21% | $30.19 Million | $52.77 Million | -12.19pp |
| 2010-12-31 | 69.40% | $54.12 Million | $77.99 Million | -3.33pp |
| 2009-12-31 | 72.73% | $89.17 Million | $122.60 Million | +55.52pp |
| 2008-12-31 | 17.21% | $15.05 Million | $87.45 Million | +15.16pp |
| 2007-12-31 | 2.04% | $3.17 Million | $155.37 Million | -39.34pp |
| 2006-12-31 | 41.39% | $70.16 Million | $169.52 Million | -27.17pp |
| 2005-12-31 | 68.55% | $62.70 Million | $91.46 Million | -3.77pp |
| 2004-12-31 | 72.32% | $92.64 Million | $128.10 Million | +33.83pp |
| 2003-12-31 | 38.49% | $24.20 Million | $62.87 Million | +19.93pp |
| 2002-12-31 | 18.56% | $10.43 Million | $56.17 Million | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more